The HARMONY Alliance is a public-private European Network established in 2017, which currently includes 53 partners and 37 associated members from 22 countries. One of the objectives of HARMONY is improving the understanding and treatment of hematological malignancies by using Big Data.
One of the work packages within HARMONY (work package 2; WP 2) is focused on defining outcomes that are relevant to each hematological malignancies considered in HARMONY.
This study aims to define a core outcome set (COS) for Non-Hodgkin lymphoma (NHL). Different stakeholders will provide their expert feedback in a Delphi survey and rank different outcomes according to their importance. The different stakeholder groups include clinicians, patients and patient advocates and members of EFPIA (European Federation of Pharmaceutical Industries and Associations).
A future use of COS can improve the comparability of clinical trials and the consistency of reporting. Therefore COS can help to ensure appropriate outcomes are measured in future clinical trials.
Lars Bullinger, WP 2 Leader, HARMONY Partner Charit? Berlin
Renate Schulze-Rath, WP 2 Leader, HARMONY Partner Bayer
HARMONY Alliance, Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
- COS for clinical trials or clinical research
- COS for practice
- Consensus meeting
- Delphi process
Multi-round Delphi process, final consensus meeting